Beyond DMD, Summit Aims For Top With Novel Antibiotics

While investors will be keeping a close eye on the 48-week read-out of the Phase II trial of Summit Therapeutics’ utrophin modulator ezutromid in patients with Duchenne muscular dystrophy, expected in the third quarter, the Oxford, UK-based biotech is increasing its interest in novel antibiotics. Company CEO Glyn Edwards caught up with Scrip at the 2018 Biotech Showcase and outlined how Summit intends to take on both DMD and develop narrow spectrum antibiotics against new targets in challenging pathogens such as Clostridium difficile.